Montelukast vs Rituximab
Montelukast vs Rituximab: Overview
This comparison examines the pharmacological differences between Montelukast and Rituximab.
Mechanism of Action
Montelukast: Selective leukotriene D4 receptor antagonist.
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Montelukast — 2.7-5.5 hours; Rituximab — 22 days.
Chemical Properties
Molecular Formula: Montelukast — C35H36ClNO3S.
Molecular Weight: Montelukast — 586.1800 g/mol.
Type: Montelukast — Small molecule; Rituximab — Antibody.